Glutathione is involved in the granular storage of dopamine in rat PC12 pheochromocytoma cells: Implications for the pathogenesis of Parkinson's disease

Journal of Neuroscience

Volumn 16, Issue 19, 1996, Pages 6038-6045

  Drukarch, Benjamin ^a   Jongenelen, Cornelis A M ^a   Schepens, Erik ^a   Langeveld, Cornelis H ^a   Stoof, Johannes C ^a  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

dopamine; glutathione; neurotransmitter uptake; oxidative stress; Parkinson's disease; PC12 cells; vesicular storage

Indexed keywords

BUTHIONINE SULFOXIMINE; DOPAMINE; GLUTATHIONE; HYDROGEN PEROXIDE; METIROSINE; RESERPINE;

ANIMAL CELL; ARTICLE; CELL STRAIN; DOPAMINE METABOLISM; GLUTATHIONE METABOLISM; NEUROTRANSMITTER RELEASE; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PHEOCHROMOCYTOMA CELL; PRIORITY JOURNAL; RAT; SECRETORY GRANULE; SYNAPSE VESICLE;

EID: 0029832436     PISSN: 02706474     EISSN: None     Source Type: Journal    
DOI: 10.1523/jneurosci.16-19-06038.1996     Document Type: Article

References (48)

1. Adams JD, Odunze IN (1991) Oxygen free radicals and Parkinson's disease. Free Radic Biol Med 10:161-169.
2. Andersen PH (1989) The dopamine uptake inhibitor GBR 12909: selectivity and molecular mechanism of action. Eur J Pharmacol 166:493-504.
3. Baker MA, Cerniglia GJ, Zaman A (1990) Microtiter plate assay for the measurement of glutathione and glutathione disulfide in large numbers of biological samples. Anal Biochem 190:360-365.
4. Birks RI, MacIntosh FC (1957) Acetylcholine metabolism at nerve-endings. Br Med Bull 13:157-161.
5. Bindoli A, Rigobello MP, Deeble DJ (1992) Biochemical and toxicological properties of the oxidation products of catecholamines. Free Radic Biol Med 13:391-405.
6. Bradford M (1976) A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
7. Carlsson A (1965) Drugs which block the storage of 5-hydroxytryptamine and related amines. Handb Exp Pharmacol 19:529-592.
8. Cubells JF, Rayport S, Rajendran G, Sulzer D (1994) Metamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular oxidative stress. J Neurosci 14:2260-2271.
9. Dexter DT, Sian J, Rose S, Hindmarsh JG, Mann VM, Cooper JM, Wells FR, Daniel SE, Lees AJ, Schapira AHV, Jenner P, Marsden CD (1994) Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease. Ann Neurol 35:38-44.
10. DiMonte DA, Chan P, Sandy MS (1992) Glutathione in Parkinson's disease: a link between oxidative stress and mitochondrial damage? Ann Neurol 32:S111-S115.
11. Dschida WJA, Bowman BJ (1995) The vacuolar ATPase: sulfite stabilization and the mechanism of nitrate inactivation. J Biol Chem 270:1557-1563.
12. Elroy-Stein O, Groner Y (1988) Impaired neurotransmitter uptake in PC12 cells overexpressing human Cu/Zn-superoxide dismutase: implication for gene dosage effects in Down's syndrome. Cell 52:259-267.
13. Erickson JD, Eiden LE (1993) Functional identification and molecular cloning of a human brain vesicle monoamine transporter. J Neurochem 61:2314-2317.
14. Gibb WRG, Lees AJ (1991) Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson's disease. J Neurol Neurosurg Psych 54:388-396.
15. Greene LA, Rein G (1977) Release, storage and uptake of catecholamines by a clonal cell line of nerve growth factor (NGF) responsive pheochromocytoma cells. Brain Res 129:247-263.
16. Greene LA, Tischler AS (1976) Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor. Proc Natl Acad Sci USA 73:2424-2428.
17. Hirsch EC, Brandel JP, Galle P, Javoy-Agid F (1991) Iron and aluminum increase in the substantia nigra of patients with Parkinson's disease: an X-ray microanalysis. J Neurochem 56:446-451.
18. Iversen LL (1973) Catecholamine uptake processes. Br Med Bull 29:130-135.
19. Jenner P (1993) Altered mitochondrial function, iron metabolism and glutathione levels in Parkinson's disease. Acta Neurol Scand 87[Suppl 146]:6-13.
20. Johnson Jr RG (1988) Accumulation of biological amines into chromaffin granules: a model for hormone and neurotransmitter transport. Physiol Rev 68:233-307.
21. Langeveld CH, Van Waas MP, Stoof JC, Sutanto W, De Kloet ER, Wolbers JG, Heimans JJ (1992) Implication of glucocorticoid receptors in the stimulation of human glioma cell proliferation by dexamethasone. J Neurosci Res 31:524-531.
22. Langeveld CH, Schepens E, Stoof JC, Bast A, Drukarch B (1995) Differential sensitivity to hydrogen peroxide of dopaminergic and noradrenergic neurotransmission in rat brain slices. Free Radic Biol Med 19:209-217.
23. Maker HS, Weiss C, Silides DJ, Cohen G (1981) Coupling of dopamine oxidation (monoamine oxidase activity) to glutathione oxidation via the generation of hydrogen peroxide in rat brain homogenates. J Neurochem 36:589-593.
24. Meister A (1991) Glutathione deficiency produced by inhibition of its synthesis, and its reversal: applications in research and therapy. Pharmacol Ther 51:155-194.
25. Meister A, Andersson ME (1983) Glutathione. Annu Rev Biochem 52:711-760.
26. Melega WP, Howard BD (1981) Choline and acetylcholine metabolism in PC12 secretory cells. Biochemistry 20:4477-4483.
27. Michel PP, Hefti F (1990) Toxicity of 6-hydroxydopamine and dopamine for dopaminergic neurons in culture. J Neurosci Res 26:428-435.
28. Nappi AJ, Vass E (1994) The effects of glutathione and ascorbic acid on the oxidations of 6-hydroxydopa and 6-hydroxydopamine. Biochim Biophys Acta 1201:498-504.
29. Olanow CW (1992) An introduction to the free radical hypothesis in Parkinson's disease. Ann Neurol 32:S2-S9.
30. Pan Z, Perez-Polo JR (1993) Role of nerve growth factor in oxidant homeostasis: glutathione metabolism. J Neurochem 61:1713-1721.
31. Peter D, Jimenez J, Liu Y, Kim J, Edwards RH (1994) The chromaffin granule and synaptic vesicle amine transporters differ in substrate recognition and sensitivity to inhibitors. J Biol Chem 269:7231-7237.
32. Pileblad E, Eriksson PS, Hansson E (1991) The presence of glutathione in primary neuronal and astroglial cultures from rat cerebral cortex and brain stem. J Neural Transm 86:43-49.
33. Redegeld FA, Van Opstal MA, Houdkamp E, Van Bennekom WP (1988) Determination of glutathione in biological material by flow-injection analysis using an enzymatic recycling reaction. Anal Biochem 174:489-495.
34. Riederer P, Sofic E, Rausch W-D, Schmidt B, Reynolds GP, Jellinger K, Youdim MBH (1989) Transition metals, ferritin, glutathione, and ascorbic acid in Parkinsonian brains. J Neurochem 52:515-520.
35. Roda LG, Nolan JA, Seung UK, Hogue-Angeletti RA (1980) Isolation and characterization of chromaffin granules from a pheochromocytoma (PC 12) cell line. Exp Cell Res 128:103-109.
36. + pumping into intracellular organelles. Annu Rev Physiol 48:403-413.
37. Rudnick G, Clark J (1993) From synapse to vesicle: the reuptake and storage of biogenic amine neurotransmitters. Biochim Biophys Acta 1144:249-263.
38. Sampath D, Jackson GR, Werrbach-Perez K, Perez-Polo JR (1994) Effects of nerve growth factor on glutathione peroxidase and catalase in PC12 cells. J Neurochem 62:2476-2479.
39. Schickler M, Knobler H, Avraham KB, Elroy-Stein O, Groner Y (1989) Diminished serotonin uptake in platelets of transgenic mice with increased Cu/Zn-superoxide dismutase activity. EMBO J 8:1385-1392.
40. Schuldiner S (1994) A molecular glimpse of vesicular monoamine transporters. J Neurochem 62:2067-2078.
41. Schuldiner S, Liu Y, Edwards RH (1993) Reserpine binding to a vesicular amine transporter expressed in Chinese hamster ovary fibroblasts. J Biol Chem 268:29-34.
42. Sofic E, Lange KW, Jellinger K, Riederer P (1992) Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci Lett 142:128-130.
43. Spector S, Sjoerdsma A, Udenfriend S (1965) Blockade of endogenous norepinephrine synthesis by alpha-methyl-tyrosine, an inhibitor of tyrosine hydroxylase. J Pharmacol Exp Ther 147:86-95.
44. Spina MB, Cohen G (1988) Exposure of school synaptosomes to L-dopa increases levels of oxidized glutathione. J Pharmacol Exp Ther 247:502-507.
45. Spina MB, Cohen G (1989) Dopamine turnover and glutathione oxidation: implications for Parkinson's disease. Proc Natl Acad Sci USA 86:1398-1400.
46. Tietze F (1969) Enzymatic method for quantification of total and oxidized glutathione: applications to mammalian blood and other tissue. Anal Biochem 27:502-522.
47. Van Muiswinkel FL, Jongenelen CAM, Schepens HTWJ, Stoof JC, Drukarch B (1995) Effects of chronic activation of dopamine D-2 receptors in cultures of rat fetal dopaminergic neurons: indications for alterations in functional activity. Dev Brain Res 85:128-136.
48. Westerink BHC, Mulder TBA (1981) Determination of picomole amounts of dopamine, noradrenaline, 3,4-dihydroxyphenylalanine, 3,4-dihydroxyphenylacetic acid, homovanillic acid, and 5-hydroxyindoleacetic acid in nervous tissue after one-step purification on Sephadex G-10, using high-performance liquid chromatography with a novel type of electrochemical detection. J Neurochem 36:1449-1462.